

HUMIRA (ADALIMUMAB) [PREFERRED]
PRIOR AUTHORIZATION FORM
 (form effective 1/3/2022)



Keystone First

PERFORMRxSM
 Next Generation Pharmacy Benefits

Fax to PerformRxSM at **1-866-497-1387**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages:	Name of office contact:
Contact's phone number:		LTC facility contact/phone:	
PATIENT INFORMATION			
Patient name:		Patient ID #:	DOB:
Street address:		Apt. #:	City/state/zip:
PRESCRIBER INFORMATION			
Prescriber name:		Specialty:	
State license #:	NPI:	MA Provider ID #	
Street address:		Suite #:	City/state/zip:
Phone:		Fax:	
CLINICAL INFORMATION			
Product requested: <input type="checkbox"/> Humira <input type="checkbox"/> Humira CF <input type="checkbox"/> other: _____			
Strength and formulation/packaging (i.e., syringe, pen, starter pack, etc.):			
Directions:		Qty:	Refills:
Diagnosis (submit documentation):		Patient's weight: _____ lbs/kg	
		Dx code (required):	
PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):			
Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:			
Pharmacy Phone #:		Pharmacy Fax #:	
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.			
INITIAL REQUESTS (Complete questions applicable to patient's diagnosis):			
1. All diagnoses: Check all that apply to the patient and submit documentation for each. <input type="checkbox"/> screened for hepatitis B (anti-HBs, HBsAg, and anti-HBc) <input type="checkbox"/> screened for tuberculosis			
2. All diagnoses: Is Humira being prescribed by or in consultation with an appropriate specialist? <input type="checkbox"/> Yes – List specialty: _____ <input type="checkbox"/> No			
3. Ankylosing spondylitis: Does the patient have a history of trial and failure of a two-week trial of continuous treatment with two different oral NSAIDs? <input type="checkbox"/> Yes – List medications tried: _____ <input type="checkbox"/> No			
4. Crohn's disease: Does at least one of the following apply to the patient? <input type="checkbox"/> moderate to severe Crohn's disease and one of the following: <input type="checkbox"/> failed to achieve remission with or has a contraindication or intolerance to an induction course of corticosteroids <input type="checkbox"/> failed to maintain remission or has a contraindication or intolerance to immunomodulators <input type="checkbox"/> has one or more high-risk or poor prognostic features <input type="checkbox"/> has achieved remission with the requested medication and will be using the requested medication as maintenance therapy to maintain remission			
5. Ulcerative colitis: Check all that apply to the patient. <input type="checkbox"/> mild UC that is associated with multiple poor prognostic factors <input type="checkbox"/> moderate-to-severe UC <input type="checkbox"/> failed to achieve remission with or has a contraindication or intolerance to an induction course of corticosteroids <input type="checkbox"/> failed to maintain remission or has a contraindication or intolerance to immunomodulators <input type="checkbox"/> has achieved remission with the requested medication and will be using the requested medication as maintenance therapy to maintain remission			
6. Rheumatoid arthritis: Does the patient have a history of trial and failure, contraindication, or intolerance of at least 3 months of treatment with methotrexate or another non-biologic DMARD? <input type="checkbox"/> Yes – List medications tried: _____ <input type="checkbox"/> No			
7. Juvenile idiopathic arthritis (JIA): Check all that apply to the patient. <input type="checkbox"/> therapeutic failure of a three-month trial of a conventional non-biologic DMARD; list medications tried: _____ <input type="checkbox"/> contraindication or intolerance to non-biologic DMARDs; provide explanation: _____ <input type="checkbox"/> systemic JIA with active systemic features <input type="checkbox"/> one or more risk factors for disease severity <input type="checkbox"/> involvement of high-risk joints (e.g., cervical spine, hip, wrist) <input type="checkbox"/> high disease activity <input type="checkbox"/> is at high risk of disabling joint damage <input type="checkbox"/> active sacroiliitis and/or enthesitis and has tried and failed a two-week trial of an oral NSAID; list medications tried: _____			

HUMIRA (ADALIMUMAB) [PREFERRED] PRIOR AUTHORIZATION FORM

INITIAL REQUESTS (Complete questions applicable to patient's diagnosis):

8. **Psoriatic arthritis:** Does at least one of the following apply to the patient?

- axial disease and/or enthesitis
- peripheral disease and has tried and failed methotrexate or other DMARD; list medications tried:
- severe disease
- concomitant moderate-to-severe nail disease

9. **Moderate to severe chronic psoriasis:** Check all that apply to the patient.

- at least 3% of body surface area (BSA) is affected
- critical areas of the body are involved (such as face, palms, soles, and/or genitals)
- significant disability or impairment of physical or mental functioning
- moderate to severe nail disease
- history of therapeutic failure, contraindication or intolerance to:
 - topical corticosteroids or other topical therapy; list medications tried or explain contraindication: _____
 - 3-month trial of oral systemic therapy; list medications tried or explain contraindication: _____
 - ultraviolet light therapy

10. **Uveitis:** Check all of the following that apply to the patient and submit documentation for each.

- has a diagnosis of uveitis associated with juvenile idiopathic arthritis or Behçet's disease
 - has steroid-dependent uveitis (i.e., requires \geq prednisone 7.5 mg daily [or equivalent]) with plan to taper or discontinue systemic steroids
 - has a documented history of trial and failure, contraindication, or intolerance of systemic immunosuppressives or corticosteroids (systemic, topical, intraocular, or periorbital)
- List medications tried: _____

11. **Hidradenitis suppurative (HS):** Check all that apply to the patient.

- Hurley stage II disease
- Hurley stage III disease
- history of therapeutic failure, contraindication, or intolerance to:
 - 3-month trial of topical clindamycin
 - adequate trial of a systemic antibiotic
- Is a candidate for or has history of surgical intervention for HS

12. **All other diagnoses:** Submit documentation supporting the use of Humira for the patient's diagnosis and other treatments tried.

RENEWAL REQUESTS

1. . Since starting Humira, has the patient experienced improvement in disease activity and/or level of functioning?

- Yes No

2. Is Humira being prescribed by or in consultation with an appropriate specialist?

- Yes - list specialty: _____
- No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.